Novartis pays $75 million to HGS as albinterferon alfa-2b heads for filing
This article was originally published in Scrip
Executive Summary
Human Genome Sciences (HGS) has earned a $75 million milestone payment from Novartis for the successful completion of the Phase III development programme for